FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS
Provided is a composition comprising a polyglycolized glyceride and a compound having the following structure (I): or a pharmaceutically acceptable salt thereof. Also provided are crystalline forms of the compound of structure (I), or a pharmaceutically acceptable salt thereof. Methods of making the same, and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated diseases, disorders or conditions are also disclosed.
1 .- 168 . (canceled)
169 . A crystalline form of a maleic acid salt or a methanesulfonic acid salt of a compound of structure (I):
170 . The crystalline form of claim 169 , wherein the maleic acid salt of the compound of structure (I) is characterized by an X-ray powder diffraction pattern substantially in accordance with the maleic acid salt shown in FIG. 19 A .
171 . The crystalline form of claim 169 , wherein the maleic acid salt of the compound of structure (I) has a differential scanning calorimetry thermogram substantially in accordance with that shown in FIG. 19 B .
172 . The crystalline form of claim 171 , wherein the differential scanning calorimetry thermogram having an endothermic event from about 174.3° C. to about 177.6° C.
173 . The crystalline form of claim 169 , wherein the maleic acid salt of the compound of structure (I) has a melting point temperature of about 174.3° C.
174 . The crystalline form of claim 169 , wherein the maleic acid salt of the compound of structure (I) has a thermogravimetric analysis characterized by a mass loss of about 4.69% when heated from about 117.4° C. to about 180.3° C.
175 . The crystalline form of claim 169 , wherein the maleic acid salt of the compound of structure (I) has a thermogravimetric analysis diagram substantially in accordance with that shown in FIG. 19 C .
176 . The crystalline form of claim 169 , wherein the methanesulfonic acid salt of the compound of structure (I) is characterized by an X-ray powder diffraction pattern substantially in accordance with the methanesulfonic acid salt shown in FIG. 20 A .
177 . The crystalline form of claim 169 , wherein the methanesulfonic acid salt of the compound of structure (I) has a differential scanning calorimetry thermogram substantially in accordance with that shown in FIG. 20 B .
178 . The crystalline form of claim 177 , wherein the differential scanning calorimetry thermogram having an endothermic event from about 206.3° C. to about 207.5° C.
179 . The crystalline form of claim 169 , wherein the methanesulfonic acid salt of the compound of structure (I) has a melting point temperature of about 206.3° C.
180 . The crystalline form of claim 169 , wherein the methanesulfonic acid salt of the compound of structure (I) has a thermogravimetric analysis characterized by a mass loss of about 4.95% when heated from about 117.6° C. to about 212.7° C.
181 . The crystalline form of claim 169 , wherein the methanesulfonic acid salt of the compound of structure (I) has a thermogravimetric analysis diagram substantially in accordance with that shown in FIG. 20 C .
182 . The crystalline form of claim 169 , wherein the crystalline form is substantially pure.
183 . The crystalline form of claim 182 , wherein the crystalline form is 99.35% pure.
184 .- 186 . (canceled)
187 . A method for treating a cancer comprising administering a therapeutically effective amount of the crystalline form of claim 169 , wherein the cancer is bladder cancer, prostate cancer, colorectal cancer, a hematological malignancy, acute myeloid leukemia, a Pim kinase-mediated cancer, or a fibrotic cancer.
188 . (canceled)